NetworkNewsBreaks – RVL Pharmaceuticals plc (NAS
Post# of 13

RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution) (“UPNEEQ”), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, will be represented at the 25th annual H.C. Wainwright Global Investment Conference. The company announced that CEO Brian Markson will be participating in a fireside chat during the event, which is scheduled for Sept. 12, 2023. Markison will also be hosting one-on-one investor meetings during the conference, which will be held in New York City. Markison’s fireside chat is slated to begin at 11:30 a.m. ET. and can be viewed by webcast, either live or following the event on a replay.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

